Leap Therapeutics Analyst Ratings
Leap Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 191.67% | HC Wainwright & Co. | $2.5 → $7 | Maintains | Buy |
| 07/13/2023 | 670.83% | Raymond James | $17 → $18.5 | Maintains | Outperform |
| 06/23/2023 | 608.33% | Raymond James | $20 → $17 | Maintains | Outperform |
| 05/16/2023 | 4.17% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 04/13/2023 | -16.67% | Mizuho | → $2 | Reiterates | → Buy |
| 03/27/2023 | 4.17% | HC Wainwright & Co. | → $2.5 | Reiterates | → Buy |
| 03/27/2023 | -16.67% | Raymond James | $2.5 → $2 | Maintains | Outperform |
| 03/17/2023 | -16.67% | Mizuho | $3 → $2 | Maintains | Buy |
| 01/27/2023 | 25% | Mizuho | $6 → $3 | Maintains | Buy |
| 01/18/2023 | 4.17% | HC Wainwright & Co. | $4 → $2.5 | Maintains | Buy |
| 11/11/2022 | 4.17% | Raymond James | $3.5 → $2.5 | Maintains | Outperform |
| 08/15/2022 | 45.83% | Raymond James | $3 → $3.5 | Maintains | Outperform |
| 07/13/2022 | 25% | Raymond James | $4 → $3 | Maintains | Outperform |
| 10/04/2021 | 150% | Mizuho | → $6 | Initiates Coverage On | → Buy |
| 09/14/2021 | 66.67% | Raymond James | $3 → $4 | Maintains | Outperform |
| 03/02/2021 | 45.83% | Raymond James | $2.5 → $3.5 | Maintains | Outperform |
| 08/17/2020 | 66.67% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 06/29/2020 | 150% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 05/19/2020 | 108.33% | HC Wainwright & Co. | $2.5 → $5 | Reiterates | → Buy |
| 03/17/2020 | 4.17% | HC Wainwright & Co. | $3.25 → $2.5 | Maintains | Buy |
| 02/11/2020 | 150% | Baird | → $6 | Initiates Coverage On | → Outperform |
| 01/08/2020 | 4.17% | Raymond James | → $2.5 | Upgrades | Market Perform → Outperform |
| 11/15/2019 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 12/19/2018 | 233.33% | Raymond James | $13 → $8 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月15日 | 191.67% | HC Wainwright公司 | $2.5→$7 | 維護 | 買 |
| 07/13/2023 | 670.83% | 雷蒙德·詹姆斯 | $17→$18.5 | 維護 | 跑贏大盤 |
| 2023/06/23 | 608.33% | 雷蒙德·詹姆斯 | $20→$17 | 維護 | 跑贏大盤 |
| 2023年05月16日 | 4.17% | HC Wainwright公司 | →$2.5 | 重申 | 購買→購買 |
| 04/13/2023 | -16.67% | 瑞穗 | →$2 | 重申 | →購買 |
| 03/27/2023 | 4.17% | HC Wainwright公司 | →$2.5 | 重申 | →購買 |
| 03/27/2023 | -16.67% | 雷蒙德·詹姆斯 | $2.5→$2 | 維護 | 跑贏大盤 |
| 03/17/2023 | -16.67% | 瑞穗 | $3→$2 | 維護 | 買 |
| 2023年1月27日 | 25% | 瑞穗 | $6→$3 | 維護 | 買 |
| 01/18/2023 | 4.17% | HC Wainwright公司 | $4→$2.5 | 維護 | 買 |
| 2022年11月11日 | 4.17% | 雷蒙德·詹姆斯 | $3.5→$2.5 | 維護 | 跑贏大盤 |
| 2022年08月15日 | 45.83% | 雷蒙德·詹姆斯 | $3→$3.5 | 維護 | 跑贏大盤 |
| 07/13/2022 | 25% | 雷蒙德·詹姆斯 | $4→$3 | 維護 | 跑贏大盤 |
| 10/04/2021 | 150% | 瑞穗 | →$6 | 開始承保 | →購買 |
| 09/14/2021 | 66.67% | 雷蒙德·詹姆斯 | $3→$4 | 維護 | 跑贏大盤 |
| 03/02/2021 | 45.83% | 雷蒙德·詹姆斯 | $2.5→$3.5 | 維護 | 跑贏大盤 |
| 2020/08/17 | 66.67% | HC Wainwright公司 | $5→$4 | 維護 | 買 |
| 06/29/2020 | 150% | 派珀·桑德勒 | →$6 | 開始承保 | →超重 |
| 2020/05/19 | 108.33% | HC Wainwright公司 | $2.5→$5 | 重申 | →購買 |
| 03/17/2020 | 4.17% | HC Wainwright公司 | $3.25→$2.5 | 維護 | 買 |
| 02/11/2020 | 150% | 貝爾德 | →$6 | 開始承保 | →跑贏大盤 |
| 1/08/2020 | 4.17% | 雷蒙德·詹姆斯 | →$2.5 | 升級 | 市場表現優於→ |
| 2019年11月15日 | - | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 2018年12月19日 | 233.33% | 雷蒙德·詹姆斯 | $13→$8 | 維護 | 跑贏大盤 |
What is the target price for Leap Therapeutics (LPTX)?
Leap Treeutics(LPTX)的目標價格是多少？
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $7.00 expecting LPTX to rise to within 12 months (a possible 191.67% upside). 11 analyst firms have reported ratings in the last year.
利普治療公司(納斯達克代碼：LPTX)的最新目標價是由HC Wainwright&Co.於2023年8月15日報道的。這家分析公司將目標價定為7美元，預計LPTX將在12個月內上漲至(可能上漲191.67%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Leap Therapeutics (LPTX)?
Leap治療公司(LPTX)的最新分析師評級是多少？
The latest analyst rating for Leap Therapeutics (NASDAQ: LPTX) was provided by HC Wainwright & Co., and Leap Therapeutics maintained their buy rating.
利普治療公司(納斯達克代碼：LPTX)的最新分析師評級由HC Wainwright&Co.提供，利普治療公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Leap Therapeutics (LPTX)?
Leap治療公司(LPTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leap Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leap Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Leap Treeutics的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Leap治療公司的上一次評級是在2023年8月15日提交的，所以你應該預計下一次評級將在2024年8月15日左右提供。
Is the Analyst Rating Leap Therapeutics (LPTX) correct?
分析師對Leap Treeutics(LPTX)的評級正確嗎？
While ratings are subjective and will change, the latest Leap Therapeutics (LPTX) rating was a maintained with a price target of $2.50 to $7.00. The current price Leap Therapeutics (LPTX) is trading at is $2.40, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Leap治療公司(LPTX)的評級保持不變，目標價在2.50美元至7.00美元之間。Leap Treateutics(LPTX)目前的交易價格為2.40美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。